Russia has announced that its candidate vaccine against SARS-CoV-2 has exhibited an efficacy rate exceeding 95 percent in an initial analysis of its clinical trial data, the Financial Times reports.
Russia has announced that its candidate vaccine against SARS-CoV-2 has exhibited an efficacy rate exceeding 95 percent in an initial analysis of its clinical trial data, the Financial Times reports.
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account?
Login Now.
Don't have a GenomeWeb or 360Dx account?
Register for Free.
Privacy Policy. Terms & Conditions. . Copyright © 2021 GenomeWeb, a business unit of Crain Communications. All Rights Reserved.